What kind of drugs does Asnib/Assiminib (Xinbeli) belong to and its clinical classification analysis

Asciminib (Asciminib) is an oral targeted drug, a BCR-ABL inhibitor, mainly used to treat patients with chronic myelogenous leukemia (CML). Unlike traditional tyrosine kinase inhibitors (TKI), asinib passes through a new STI-571 binding pocket ( STAMP mechanism) selectively inhibits BCR-ABL kinase activity, thereby blocking the proliferation and survival of leukemia cells.

In terms of clinical classification, asinib is classified as a targeted therapy drug, specifically targeting the abnormal signaling pathway in leukemia caused by the BCR-ABL fusion gene. Its main advantage is that it can act on CML patients who are resistant to first- and second-generation TKIs, especially those with T315I mutations or multi-drug resistance mutations, providing new treatment options.

Different from traditional chemotherapy, Asnib is a molecularly targeted drug in the category of precision medicine. It has a specific mechanism of action, high targeting, and relatively little impact on normal hematopoietic cells. Clinical trials have shown that it can effectively delay disease progression and improve the molecular response rate (MR) and progression-free survival (PFS) of patients with chronic phase CML.

In addition, the oral administration method of asinib is convenient for patients to maintain long-term treatment, and it can be used in combination with other drugs to enhance the efficacy. Its safety is generally controllable, but attention needs to be paid to hematology and liver function indicators. Through reasonable dose adjustment and regular monitoring, asinib provides an important targeted therapy option for patients with drug resistance or intolerance to traditional TKIs in the clinical application of chronic myelogenous leukemia.

Reference link:https://www.drugs.com